Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price lifted by research analysts at Citizens Jmp from $8.00 to $12.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp‘s price target suggests a potential upside of 49.25% from the stock’s current price.

Several other research analysts have also issued reports on the company. TD Cowen increased their price target on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, August 24th. HC Wainwright boosted their price objective on Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. Robert W. Baird upped their target price on Iovance Biotherapeutics from $6.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Mizuho upped their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Finally, Wells Fargo & Company increased their target price on Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.80.

Iovance Biotherapeutics Price Performance

IOVA stock opened at $8.04 on Friday. The stock has a market capitalization of $3.64 billion, a PE ratio of -15.17 and a beta of 0.88. The company’s 50-day moving average is $11.37 and its 200-day moving average is $5.97. Iovance Biotherapeutics has a 1 year low of $2.08 and a 1 year high of $15.37.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. Iovance Biotherapeutics had a negative return on equity of 30.68% and a negative net margin of 58.20%. The business had revenue of $121.47 million during the quarter, compared to analyst estimates of $115.98 million. Iovance Biotherapeutics’s revenue was up 64.8% compared to the same quarter last year. On average, analysts anticipate that Iovance Biotherapeutics will post -0.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Clearwater Capital Advisors LLC bought a new position in Iovance Biotherapeutics in the 3rd quarter valued at about $322,000. Russell Investments Group Ltd. increased its holdings in Iovance Biotherapeutics by 165.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 513,032 shares of the biotechnology company’s stock worth $7,603,000 after purchasing an additional 319,979 shares in the last quarter. Brighton Jones LLC increased its holdings in Iovance Biotherapeutics by 5.1% during the 3rd quarter. Brighton Jones LLC now owns 40,069 shares of the biotechnology company’s stock worth $594,000 after purchasing an additional 1,954 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in Iovance Biotherapeutics by 867.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 416,539 shares of the biotechnology company’s stock worth $6,043,000 after purchasing an additional 373,491 shares in the last quarter. Finally, Kestra Advisory Services LLC raised its stake in shares of Iovance Biotherapeutics by 25.2% in the third quarter. Kestra Advisory Services LLC now owns 42,150 shares of the biotechnology company’s stock worth $625,000 after purchasing an additional 8,483 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.